Document Detail


Contribution of IL-33 to induction and augmentation of experimental allergic conjunctivitis.
MedLine Citation:
PMID:  20501612     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
IL-33, a member of the IL-1 family of cytokines, is the ligand for ST2 (IL-33Ralpha chain). IL-33 has the capacity to induce T(h)2 cytokine production from T(h)2 cells, mast cells and basophils, indicating that IL-33 has the potential to induce T(h)2 cytokine-mediated allergic inflammation of the eye. Thus, we tested the pathological role of IL-33 in allergic conjunctivitis (AC). As reported elsewhere, animals immunized with ragweed pollen (RW)/alum and boosted with RW/PBS developed AC promptly (within 15 min) and conjunctival eosinophilic inflammation after a delay (within 24 h) in response to eye drop challenge with RW. Furthermore, RW-immunized mice, when topically challenged with both RW and IL-33, developed more striking eosinophilia in their conjunctiva without exacerbation of the clinical AC score. This in vivo IL-33 treatment significantly increased the capacity of T cells in the cervical lymph nodes of RW-immunized mice to produce IL-4, IL-5 and IL-13 upon challenge with anti-CD3 and anti-CD28 antibodies in vitro. Furthermore, the infiltrating cells were largely eosinophils and a small proportion of CD4(+) T cells, both of which express ST2. We also found that even splenic eosinophils express ST2 and show increased expression in response to IL-5, granulocyte-macrophage colony-stimulating factor (GM-CSF) or IL-33. Eosinophils, stimulated with IL-5 and/or GM-CSF, are responsive to IL-33, which induces production of IL-4 and chemokines. Finally, we showed that conjunctival tissues constitutively express biologically active IL-33, suggesting that IL-33 might play a crucial role in the induction and augmentation of AC.
Authors:
Saori Matsuba-Kitamura; Tomohiro Yoshimoto; Koubun Yasuda; Shizue Futatsugi-Yumikura; Yuuko Taki; Taichiro Muto; Tomohiro Ikeda; Osamu Mimura; Kenji Nakanishi
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-05-25
Journal Detail:
Title:  International immunology     Volume:  22     ISSN:  1460-2377     ISO Abbreviation:  Int. Immunol.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-05-28     Completed Date:  2010-11-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8916182     Medline TA:  Int Immunol     Country:  England    
Other Details:
Languages:  eng     Pagination:  479-89     Citation Subset:  IM    
Affiliation:
Department of Immunology and Medical Zoology, Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alum Compounds / administration & dosage
Ambrosia
Animals
Antigens, Plant / administration & dosage,  immunology
CD4-Positive T-Lymphocytes / drug effects*,  immunology,  metabolism,  pathology
Conjunctiva / drug effects*,  immunology,  metabolism,  pathology
Conjunctivitis, Allergic / immunology*,  physiopathology
Cytokines / biosynthesis,  genetics,  secretion
Eosinophilia
Humans
Immunization, Secondary
Interleukins / administration & dosage*
Lymphocyte Activation / drug effects
Mice
Mice, Inbred BALB C
Models, Animal
Pollen / immunology
Receptors, Interleukin / genetics,  metabolism*
Chemical
Reg. No./Substance:
0/Alum Compounds; 0/Antigens, Plant; 0/Cytokines; 0/Il1rl1 protein, mouse; 0/Interleukins; 0/Receptors, Interleukin; 0/interleukin-33, mouse; 10043-01-3/aluminum sulfate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  MT6-MMP is present in lipid rafts and faces inward in living human PMNs but translocates to the cell...
Next Document:  AACR-FDA-NCI CANCER BIOMARKERS COLLABORATIVE ADVANCING THE USE OF BIOMARKERS IN CANCER DRUG DEVELOPM...